CHOUEIRI, T. K., Y. ZAKHARIA, S. PAL, J. KOCSIS, R.. PACHYNSKI, Alexandr POPRACH, A. B. NIXON, Y. M. LIU, M. STARR, J. LYU, K. OWZAR, M. DESHAZO, P. LARA, L. GECZI, T. H. HO, M. WALSH, B. ADAMS, L. ROBERTSON, M. DARIF, C. THEUER and N. AGARWAL. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). ONCOLOGIST. DURHAM: ALPHAMED PRESS, 2021, vol. 26, No 7, p. "560"-"e1103", 7 pp. ISSN 1083-7159. Available from: https://dx.doi.org/10.1002/onco.13777. |
Other formats:
BibTeX
LaTeX
RIS
@article{1786842, author = {Choueiri, T. K. and Zakharia, Y. and Pal, S. and Kocsis, J. and Pachynski, R.. and Poprach, Alexandr and Nixon, A. B. and Liu, Y. M. and Starr, M. and Lyu, J. and Owzar, K. and DeShazo, M. and Lara, P. and Geczi, L. and Ho, T. H. and Walsh, M. and Adams, B. and Robertson, L. and Darif, M. and Theuer, C. and Agarwal, N.}, article_location = {DURHAM}, article_number = {7}, doi = {http://dx.doi.org/10.1002/onco.13777}, keywords = {Phase II; TRAXAR; Axitinib; Renal cell cancer; Endoglin; TRC105; Carotuximab}, language = {eng}, issn = {1083-7159}, journal = {ONCOLOGIST}, title = {Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)}, url = {https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1002/onco.13777}, volume = {26}, year = {2021} }
TY - JOUR ID - 1786842 AU - Choueiri, T. K. - Zakharia, Y. - Pal, S. - Kocsis, J. - Pachynski, R.. - Poprach, Alexandr - Nixon, A. B. - Liu, Y. M. - Starr, M. - Lyu, J. - Owzar, K. - DeShazo, M. - Lara, P. - Geczi, L. - Ho, T. H. - Walsh, M. - Adams, B. - Robertson, L. - Darif, M. - Theuer, C. - Agarwal, N. PY - 2021 TI - Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR) JF - ONCOLOGIST VL - 26 IS - 7 SP - "560"-"e1103" EP - "560"-"e1103" PB - ALPHAMED PRESS SN - 10837159 KW - Phase II KW - TRAXAR KW - Axitinib KW - Renal cell cancer KW - Endoglin KW - TRC105 KW - Carotuximab UR - https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1002/onco.13777 N2 - Lessons Learned The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)-targeted therapies. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors. Methods TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 Results A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. Conclusion The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment. ER -
CHOUEIRI, T. K., Y. ZAKHARIA, S. PAL, J. KOCSIS, R.. PACHYNSKI, Alexandr POPRACH, A. B. NIXON, Y. M. LIU, M. STARR, J. LYU, K. OWZAR, M. DESHAZO, P. LARA, L. GECZI, T. H. HO, M. WALSH, B. ADAMS, L. ROBERTSON, M. DARIF, C. THEUER and N. AGARWAL. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). \textit{ONCOLOGIST}. DURHAM: ALPHAMED PRESS, 2021, vol.~26, No~7, p.~''560''-''e1103'', 7 pp. ISSN~1083-7159. Available from: https://dx.doi.org/10.1002/onco.13777.
|